Evidence map›Paper›PMID 32210228›Full record

ArticleNature communications2020

Subpopulation targeting of pyruvate dehydrogenase and GLUT1 decouples metabolic heterogeneity during collective cancer cell invasion.

R Commander, C Wei, A Sharma, J K Mouw, L J Burton, E Summerbell, D Mahboubi, R J Peterson, J Konen, W Zhou and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
5.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Collective migration modes in development, tissue repair and cancer.Nature reviews. Molecular cell biology · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

R Commander *Graduate Program in Cancer Biology, Emory University, Atlanta, GA, USA.
C Wei *Winship Cancer Institute, Emory University, Atlanta, GA, USA.
A SharmaWinship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3021-9866
J K MouwWinship Cancer Institute, Emory University, Atlanta, GA, USA.
L J BurtonWinship Cancer Institute, Emory University, Atlanta, GA, USA.
E SummerbellGraduate Program in Cancer Biology, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-1336-1433
D MahboubiGraduate Program in Molecular Systems Pharmacology, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9279-997X
R J PetersonGraduate Program in Biochemistry, Cell and Developmental Biology, Emory University, Atlanta, GA, USA.
J KonenDepartment of Thoracic/Head & Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
W ZhouWinship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6783-9957
Y DuWinship Cancer Institute, Emory University, Atlanta, GA, USA.
H FuWinship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2362-7979
M ShanmugamWinship Cancer Institute, Emory University, Atlanta, GA, USA. mala.shan@emory.edu.ORCID http://orcid.org/0000-0002-4415-8083
A I MarcusWinship Cancer Institute, Emory University, Atlanta, GA, USA. aimarcu@emory.edu.
Emory University · USEmory Healthcare · USThe University of Texas MD Anderson Cancer Center · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Systems analysis of phenotypic switch in control of cancer invasionU54CA209992 · NCI · YALE UNIVERSITY · PI LEVCHENKO, ANDRE · 2016 to 2021
$10.1M
Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbationU01CA217875 · NCI · EMORY UNIVERSITY · PI FU, HAIAN · 2017 to 2021
$4.5M
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer S1R01CA201340 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.0M
Implications of Metabolic Regulation of BCL-2 Dependence for Myeloma TherapyR01CA208328 · NCI · EMORY UNIVERSITY · PI SHANMUGAM, MALATHY (MALA) · 2017 to 2021
$1.9M
Atypical Angiogenic Mimicry During Collective Lung Cancer InvasionR01CA236369 · NCI · EMORY UNIVERSITY · PI MARCUS, ADAM I. · 2019 to 2023
$1.8M
NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA201340NCI NIH HHS R01 CA208328NCI NIH HHS R01 CA236369NCI NIH HHS U01 CA217875NCI NIH HHS U54 CA209992
6 · The paper itself

Abstract

Phenotypic heterogeneity exists within collectively invading packs of tumor cells, suggesting that cellular subtypes cooperate to drive invasion and metastasis. Here, we take a chemical biology approach to probe cell:cell cooperation within the collective invasion pack. These data reveal metabolic heterogeneity within invasive chains, in which leader cells preferentially utilize mitochondrial respiration and trailing follower cells rely on elevated glucose uptake. We define a pyruvate dehydrogenase (PDH) dependency in leader cells that can be therapeutically exploited with the mitochondria-targeting compound alexidine dihydrochloride. In contrast, follower cells highly express glucose transporter 1 (GLUT1), which sustains an elevated level of glucose uptake required to maintain proliferation. Co-targeting of both leader and follower cells with PDH and GLUT1 inhibitors, respectively, inhibits cell growth and collective invasion. Taken together, our work reveals metabolic heterogeneity within the lung cancer collective invasion pack and provides rationale for co-targeting PDH and GLUT1 to inhibit collective invasion.

Indexed as

AnimalsCell CommunicationCell Line, TumorCell MovementCell ProliferationGene Knockdown TechniquesGlucoseGlucose Transporter Type 1HumansLung NeoplasmsMiceNeoplasm InvasivenessOxidative PhosphorylationPyruvate Dehydrogenase (Lipoamide)RNA, Small InterferingSpheroids, CellularGlucoseGlucose Transporter Type 1pyruvate dehydrogenase E1alpha subunitPyruvate Dehydrogenase (Lipoamide)RNA, Small InterferingSLC2A1 protein, human

Identifiers

PMID32210228
PMCPMC7093428
OpenAlexW3013400044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.